While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales ...

Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Novo Nordisk's next-gen obesity drug, CagriSema, faces trial challenges with dosage flexibility and trial length as side-effects remain controlled. Investor skepticism arose from weaker-than-expected ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rallied 4% in early Copenhagen trade. Ozempic's 33.85 billion kroner of sales compared to analyst expectations of 33.34 billion kroner, and Wegovy's 19.87 billion ...

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year.

Find insight on Novo Nordisk, GSK and more in the latest Market Talks covering Health Care.

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...